BiotechTube

INT230-6

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 21/100
21
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Breast Cancer

Conditions

Breast Cancer

Trial Timeline

Mar 25, 2021 → Mar 1, 2023

NCT ID
NCT04781725

About INT230-6

INT230-6 is a phase 2 stage product being developed by Intensity Therapeutics for Breast Cancer. The current trial status is unknown. This product is registered under clinical trial identifier NCT04781725. Target conditions include Breast Cancer.

What happened to similar drugs?

20 of 20 similar drugs in Breast Cancer were approved

Approved (20) Terminated (4) Active (0)
✅arzoxifeneEli LillyApproved
✅Eribulin Injection [Halaven] + Paclitaxel injectionEisaiApproved
✅Eribulin mesylateEisaiApproved
✅Eribulin MesylateEisaiApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI)Eli LillyApproved
✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved
✅Abemaciclib + Fulvestrant + Standard ChemotherapyEli LillyApproved

Hype Score Breakdown

Clinical
12
Activity
4
Company
5
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04781725Phase 2UNKNOWN

Competing Products

20 competing products in Breast Cancer

See all competitors
ProductCompanyStageHype Score
Intratumoral Mitazalimab + Intratumoral NivolumabAlligator Bioscience ABPhase 1
26
FulvestrantDr. Reddy's LaboratoriesPre-clinical
19
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
LymphoseekNavidea BiopharmaceuticalsPhase 3
30
ALT-P7 (HM2-MMAE)AlteogenPhase 1
29
Biomarkers blood, urine and microbiota samplesEli LillyPre-clinical
30
gemcitabine + paclitaxel + bevacizumabEli LillyPhase 2
35
Gemcitabine + Adriamycine + PaclitaxelEli LillyPhase 2
35
Abemaciclib + FulvestrantEli LillyPhase 2
27
VS-6766 + Abemaciclib + FulvestrantEli LillyPhase 1/2
39
gemcitabine + vinorelbineEli LillyPhase 2
35
Abemaciclib + Fulvestrant + PlaceboEli LillyPhase 3
44
Azenosertib + Carboplatin + PembrolizumabZentalis PharmaceuticalsPhase 1/2
26
AbemaciclibEli LillyPre-clinical
26
pemetrexed + cyclophosphamide + doxorubicin + docetaxelEli LillyPhase 2
35
arzoxifeneEli LillyApproved
43
BBI-355 + Erlotinib + Futibatinib + BBI-825Boundless BioPhase 1
23
BBI-940 + FulvestrantBoundless BioPhase 1
26
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + FulvestrantEli LillyPhase 3
47
pemetrexed + gemcitabineEli LillyPhase 2
35